Closed IPO of 9,085,000 shares of common stock at $16.00 per share, for approximately $145.4 million

Research is the seed capital for creating knowledge to foster innovation: FY19 Annual Report for Duke New Ventures

From the rise of the internet to a booming digital economy: FY19 Annual Report in Software

Cohere Med licenses technology from Duke to drive adoption of early Sepsis detection using AI

PhaseBio is a clinical-stage biopharmaceutical company founded by Duke inventors Drs. Chilkoti and Setton

Venture Day Showcased 8 Duke Start-ups in Biotech & Therapeutics

Gastroenterology and engineering professionals brainstormed engineering solutions to medical problems

The Bill Gates-backed company relies on metamaterials technology developed out of David Smith Labs

Immense computing power on the cloud may not be far off, says IonQ COO.

New dyes developed on the NovaFluor platform enable researchers to radically increase in the number of scientific questions they can answer

Robots that can rapidly plan out their movements could accelerate factory automation—and help keep fragile humans safe.

Enzyvant has an exclusive worldwide licensing agreement with Duke to develop RVT-802 developed by M. Louise Markert, M.D., Ph.D.

Scientists have identified a plant hormone, beta-cyclocitral, that makes tomato and rice plant roots grow faster and branch more

Supercomputer code successfully models behavior of interwoven vasculature created with new 3D printing technique

A bioengineer from Duke has been developing a “patch” that could take the place of the cells destroyed by a heart attack